Aryl phosphate derivatives with selective activity against adenovirus and hiv
CA 2489357 A1 · Owner: Parker Hughes Institute · Inventors: Uckun, Fatih M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods and compositions for treating ADV infections and HIV/ADV co-infections by administering an aryl phosphate derivative of d4T having an electron withdrawing substituent on the aryl group and an amino acid substituent on the phosphate group are described. Preferred aryl phosphate derivatives of d4T are d4T-5~-p-bromophenyl methodyalaninyl phosphate and d4T-5~-p-chlorophenyl methoxyalaninyl phosphate.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 11, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 11, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 11, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.